In Recognition of all the Great Women Leading Agatha’s Future

Happy International Women's Day

Sunday, March 8, 2020, was International Women’s Day and it’s a day that we recognize at Agatha not just to celebrate all the women in the world who are doing great things for their companies and their families but to also recognize the hard work and efforts of the women who work at Agatha directly.

Cheimi Kamakura, CEOAgatha’s employee base comprises 60% of females, many of them in leadership roles. These women help drive the efforts to build Agatha’s products and services to be the next generation of life sciences applications, a new generation of applications that help life sciences companies manage their information better, so they can focus their time on helping save lives.

Agatha has a motto: “Contributing to a healthy life for people around the world.”

Today, we thought we’d take a minute to recognize some of the great women who work at Agatha, including:

Agatha started in 2015 with a simple idea – to help life sciences companies that performed clinical research and clinical trials across the world to effectively manage their information.

Digital transformation is about improving technology, strategies, and processes. For companies involved in clinical trials, a major goal has been to digitize documentation to improve information management, including to support compliance and regulatory requirements. Agatha’s applications for clinical trials, standard operation procedures, quality, and regulatory management are designed to support this transformation as easily and quickly as possible without great expense. We would rather see life sciences companies such as pharma, biotechs, hospitals, and others focus their attention on better treatments and medicine, than worrying where and how to store all their documentation.

Kamakura has spent almost 20 years working on and building better applications for life sciences. With Agatha, she is building a company that believes in the well being of people across the world, including Japan, the US, and the EU. Under her leadership, Agatha has made a commitment to support women and other people with limited work opportunities to help build this better world.

So from all of us at Agatha, we say thank you to Chiemi, and to all the women in Agatha and everywhere who strive to make us all better people.

Addressing Compliance Requirements at Tohoku University Hospital

Case Study: Tohoku University

When the Clinical Research Data Center at Tohoku University Hospital needed a more efficient and effective way to manage clinical and quality documents, they chose Agatha.

Located in Sendai, Japan, Tohoku University Hospital is a general hospital that belongs to a national university corporation. It has a 190-year history, the longest among university hospitals in Japan. Designated as a Clinical Research Core Hospital, it plays a major role in conducting global standard clinical research in accordance with the Medical Care Law.

The Clinical Research Data Center assists in managing data and documents for clinical research projects at the hospital. They offer consulting services related to quality control and statistics to ensure the reliability of the clinical results, as well as support for investigators in creating protocols, CRFs, entering and assigning subjects, progress management, data management, monitoring, statistical analysis, creating reports and other tasks.

For the Center, managing documents manually for many research projects imposed a great workload. Individual projects had their own document management schemes and folder structures and tamper prevention and version control were not ensured systematically. The result was high costs, slow processes, and compliance risks.

Addressing Requirements with Agatha Applications

When the Center set out to look for a solution, the goals were to streamline operations, enhance compliance, reduce wasted time, and enable collaboration with external study stakeholders.

After a review of options, they chose Agatha and implemented Agatha’s applications for managing SOPs, quality processes, and clinical research documents.

Implementing Agatha applications addressed all their requirements and allowed the Clinical Research Data Center to achieve ISO9001 certification. The applications embed best practices and required procedures, a big improvement over trying to ensure consistency by imposing rules on staffers to do so manually.

Also, because they support many investigators and research projects, a unified approach using Agatha means the Center can be more efficient, provide more services to more projects, and help accelerate each study.

A Q&A with the Prof. Takuhiro Yamaguchi, Director of the Clinical Research Data Center, and Junya Kimura, Medical Information Expert

How did you manage these processes and documents before?

Previously, we managed documents and files on Windows file servers in the data center. This posed a great burden on us, as we had to enforce rigorous rules for filenames and storage, and what’s more, we had to keep the original paper documents for some of them. So, we decided to deploy a system that has version control and anti-tampering features to enhance our document management scheme.

And how do you use Agatha applications?

We use Agatha in two areas. One is our QMS documents and SOPs, and the other is research project documents.

We used to keep paper documents as the originals for QMS documents and SOPs, and we would save electronic files chronologically, our naming rule being ‘file server + document name + date.’ With Agatha, the staffers create documents, upload them to Agatha, and the director approves them on the system. Agatha doesn’t allow us to edit wrong versions or intentionally tamper with documents, because all transactions are logged in the system. So now, we can secure the reliability of documents automatically, rather than manually as before. We use an electronic signature for documents.

How are things different now?

Now, staffers can view the latest versions of QMS documents and SOPs on Agatha. We’re currently shifting from paper to digital for clinical study documents. We conduct projects that are already underway as before and start new projects on Agatha. We are now able to manage documents of all projects systematically by a standardized scheme, as it applies to all projects, using the same folder structure across them. Before each project, or each staffer had their own storage locations and folder structures, but now we have a standard management framework. So, it’s now easier when a new staffer is assigned to a project, as everyone knows where documents should be.

Currently, our staffers upload documents sent by researchers onto Agatha to manage them there. But we’re also planning to implement new processes so that investigators can upload, review and approve documents themselves.

What benefits did you get when you started using Agatha?

The great thing was we were able to share documents from anywhere, without a hitch, when the Tokyo Office of Tohoku University was launched in July. We believe it would have been impossible to share documents with the Tokyo Office without Agatha, and this could have created the bottleneck.

Also, now we have ISO 9001 certification, and our staffers are far more self-aware about document management now. Having a DMS made some things effortless and automatic, while it made us do some things consciously. This made us think about document version control, storage, and ID and password management, and other security matters.

For example, the official document approval procedure requires drafting, review, and electronic signature for approval. We’re now fully aware of the meaning of approval and signature.

By having Agatha, we also became able to systematically manage documents by making use of the system’s features such as version control, anti-tampering, and approval logs. But it goes beyond that. It was a great gain for us that the entire staff came to understand the benefits and risks of document management and systems from using Agatha… so the impact was not just through processes, but also in the awareness of the importance of those processes by the team members.

Download the Tohoku University Customer Story for your reference.

Buying Enterprise Software? Don’t Ask for a Sandbox

a Sandbox is for kids, not enterprise software

I try not to count them, but I think I have been in the enterprise software business for about 35 years. And if it is more, please keep it to yourself. One thing I know is that we are all too old for a sandbox.

The buying and selling of software for businesses has changed little over the years. Trade shows and site visits create leads, salespeople call, demos are scheduled, and proposals are written. Sometimes customers ask for a period in which they can try the software out, like a test drive on a new Honda Accord. And as they say, “not that there’s anything wrong with that.”
I am all for trying before buying. Just don’t ask me for a sandbox.

The term sandbox evolved in our industry to mean an instance of the software that the prospective user can have access to and “play in” with dummy data. Here is my issue: No one should play with enterprise software without appropriate orientation, some training and a set of realistic scenarios. I am sorry, but this is not Candy Crush, this is business software for specific processes.

I am on a crusade for how we in the enterprise business applications market buy and sell software. I want EVERY PROSPECTIVE BUYER to use the software first. As a SaaS solution, we can create a new instance and provide credentials in minutes. HOWEVER… our pilots, for which we do not charge, include three full orientation, training, and Q&A sessions. We make parameter changes to the environment to mimic the customer’s needs. And we have an expert available 24/7 to jump in and help the users during the pilot period.

Excuse my English, but this ain’t no stinking sandbox. I don’t want users to play with the software; I want them to experience it in real-life scenarios. And I want to use the pilot period to collect information on any parameter changes that will be needed to transition into production use.

This way, a pilot project provides the benefit of accelerating the actual project. It provides momentum and a head start, so after the decision, it is not a matter of starting over. The PILOT is just the first phase of the PROJECT!

To me, this is how the current generation of modern business applications should be bought and sold. And the reason may surprise you. As a vendor, if my software is not a great fit, I actually do not want you to license it. This is SaaS software, with an annual subscription, and if it isn’t right for you, you will get frustrated, require a lot of support and chances are you will not renew your subscription.

No. I am looking for serious buyers willing to invest the time to exercise the application thoroughly. For those buyers, the sky’s the limit. No cost for the pilot, a choreographed experience with training, check-ins and unlimited support — a one-on-one session every day of the pilot if you want!

So there will be no sandboxes. Sandboxes are for children. If I have it my way, in the future we will all be buying and selling enterprise business applications as adults, with comprehensive pilot projects as the basis for the decision. Even if it takes until I have been in this industry for ANOTHER 35 years 🙂

Ready to learn more about Agatha’s approach to software trials for eTMF, SOP and more? Sign up here.

When it Comes to eTMF, it is All About Usability

Usability in trial management software

In choosing a title for this blog, I REALLY wanted to call it, “It’s Usability, Stupid.” But I recently had my two young nephews here, and they told me that “stupid” is a bad word and I should not say it… so there you go.

James Carville coined the phrase “it’s the Economy, Stupid” in 1992 to guide Bill Clinton’s presidential race. The blunt phrase aptly captured that there is one thing that trumps all in presidential elections.

And so it is with implementing and adopting eTMF solutions. Vendors focus on features because that is one way that customers compare systems. It is kind of like new features on a car where the latest version of lane tracking becomes a differentiator – vendors are eager to add a new feature that another vendor does not have.

But here is the thing: Features do not matter if users are not using the software. A new feature used by one user provides little value if a sizable percentage of users are not using the system at all. It is the 80-20 rule in action. In every software system, 80 percent of the users are using 20 percent of the features and capabilities — or are avoiding the system altogether because it is a pain in the posterior (another nod to my nephews).

With software, great design and usability is the single most important factor in determining return on investment (ROI), because fast and effective adoption drives value. So, in every way, “It’s usability, stupid.”

What does that mean in practical terms? It means that when choosing an eTMF solution, trying it first is an essential step in the selection process. Insist on a period when you can work with the tool, using it every day for a few weeks to create new artifacts, route items for approval and do quality checks. Include the CRAs and get them excited about the application. Choose a system that is easy to get started with and easy to adapt to your needs. Avoid the products that require months of work to implement.

Then you need to focus on evangelism during the rollout. Identify the leaders who are adopting the new solution quickly and recognize them enthusiastically and publicly. Identify the laggards and reach out to them quietly and privately to identify the obstacles they are encountering. This is a critical time for investment in activities that will encourage use and prevent frustration.

Of course, the starting point has to be an eTMF system with a great design and user experience baked in — that goes without saying. But it also goes without saying that some solutions available sport a real retro feel… a cool thing in a car but with software — not so much. 🙂

At Agatha we make sure that every application we build is easy to use so you can focus on your work, not using the application. Want to learn more? Sign up for a trial and we can get you set up.

Agatha Welcomes Ken Lownie To Lead North American Operations


Boston, USA; Tokyo, Japan; Lyon, France, January 22, 2020. Agatha, a provider of business applications for life sciences companies, announced today that Ken Lownie has joined the company as its head of North American Operations. Lownie is an enterprise software executive with previous experience navigating companies through periods of rapid growth. He will be responsible for sales, customer success, and operations in North America.

Agatha is experiencing strong growth in Japan, the EU, and the US. It recently received an investment of an additional $4 million; among the investors is Salesforce Ventures. The funds will be used to drive customer success worldwide, including the US and Canada.

According to Guillaume Gerard, Agatha’s COO, the US market is a key focus area for the company.

“We have a solid base of customers in the US. We have proven that our position in the market as a provider of ready-to-use, cloud-based applications is very attractive to life sciences companies, and we expect that North America will rapidly become our biggest market”.

Lownie’s mission is to leverage Agatha’s ability to provide cloud-based, ready-to-use applications to grow the US business.

“Agatha is clearly poised for a period of rapid growth. When it comes to tasks like managing clinical trial TMF documents, SOPs and quality documents, customers are looking for ready-to-use applications, not platforms. They are done with complex, expensive systems that require a lot of time, money and effort to configure and customize,” said Ken Lownie.

More Information

About Agatha, Inc.

Agatha, Inc. is a leading strategic software solutions provider to the healthcare and life sciences industry. Agatha is dedicated to helping the world’s Hospitals, biotechnology, pharmaceutical, contract research organizations, and medical device firms optimize the management of their Quality, Regulatory and Clinical documentation and processes.

Press Inquiries Contact:
Barb Mosher Zinck
phone: 1 978.618.2363

The State of Life Sciences Software with Ken Lownie, Head of North American Operations

Life Sciences Applications

Ken Lownie recently joined Agatha as the head of North American Operations. We caught up with him to get his perspective on the state of software solutions for Life Sciences companies.

Editor: Hi Ken, Welcome back!

Ken Lownie: Thanks a lot. I am really excited to be back in the health tech space. I’m passionate about helping life sciences companies implement effective, smart software solutions.

Ed: You have been away from the life sciences market for about five years. What do you see that has changed in that time?

KL: Well, I can’t speak to the whole market — there is an extraordinary array of software products sold to life sciences companies — but in the one space that I know, core content management solutions, a lot has changed, very quickly.

The market has gone through a lot of change over the last thirty years, starting in the 90s when companies were buying broad document management platforms like Documentum, OpenView, and FileNet. Some companies were even building solutions for themselves to address areas like SOP and TMF management. Over time, the market shifted and companies started buying those solutions [SOP and TMF] as “modules” instead of building them and that still happens. More recently though, there was another shift to buying these modules as SaaS solutions. Veeva is an example of one of these SaaS vendors.

The need to make it easier from an IT perspective to implement these types of business software solutions has driven many of these evolutionary changes. And now I think we are on the threshold of a new wave of solutions.

Ed: When you say a new wave, what do you mean?

KL: As I said, most of the changes in this space have been driven by a need to make it easier to implement these solutions from an IT perspective, or to avoid having to deal with the IT department at all. But the need to make business applications much easier for the business side will drive this next wave. I think of it as the consumerization of these solutions, where they become user-friendly applications, ready to use out of the box, similar to many of the consumer applications we use today.

Ed: So if these apps are ready-to-use, how do you customize them to reflect the organization’s own business processes? Traditionally, business applications go through a period of customization and configuration before they are deployed to users.

KL: The idea is that you can START using them immediately, and then easily adapt them through parameter changes. You shape these kinds of adaptive applications to reflect your preferences and processes as you use them, instead of requiring an extensive project to analyze, predict and encode specific processes. In this way, it is a learning environment, with the system adapting to the organizations incrementally. The result is immediate productivity and payback, AND increasing value over time, all of which leads to the highest ROI.

Ed: I suspect this has something to do with why you joined Agatha?

KL: Yes, absolutely. I think Agatha’s approach — cloud-based applications ready to use and easy to adapt — is right where the market is heading. And my passion is seeing software deliver benefits in terms of increased efficiency, better processes and, ultimately faster time to delivering benefits to patients.

Beyond that Agatha has a great business in Japan and a solid base of business in the EU and in the US. It is clearly poised for a period of rapid growth. Nothing is as exciting as navigating the rapid growth period of a company. So I know this will be a lot of fun and will provide me the chance to work with a lot of innovative biotech, medical device, and pharma companies.

Ed: Thanks a lot Ken, I hope we get a chance to talk again in a few months and see how things are progressing.

KL: Thank you. It is great to talk about this market space. It is so dynamic, and so energized.

MABLINK BIOSCIENCE adopte les solutions logicielles Agatha

Mablink partnership

Lyon, France, Boston, US, Tokyo, Japon, 10 janvier 2020 – Agatha Inc., un leader mondial des solutions de gestion de la qualité et du contenu pour les sciences de la vie, annonce aujourd’hui que Mablink Bioscience, une société de biotechnologie basée en France spécialisée en immuno-oncologie, adopte la solution d’Agatha.

“Mablink a pour objectif de démocratiser le développement d’ADC de 3e génération, qui sont une nouvelle classe de médicament contre le cancer. “En nous équipant de la solution de gestion documentaire développée par Agatha Life, nous voulons nous donner la possibilité de scaler très vite et de pouvoir gérer professionnellement les demandes de nos clients. Cette volonté de structurer dès le départ notre activité fait partie de la stratégie de développement de Mablink”, indique Jean-Guillaume Lafay, CEO de Mablink

L’approche de Mablink repose sur son expertise en chimie, pharmacologie et immuno-oncologie, ce qui lui permet de couvrir l’ensemble de la chaîne de valeur de la conception d’ADC de 3e génération. Sur le plan international, l’attente est forte de la part des laboratoires pharmaceutiques et des sociétés de biotechnologies.

Selon Guillaume Gerard, Directeur Executif d’Agatha, Inc., les innovateurs comme Mablink doivent disposer de solutions rapides à déployer et faciles à utiliser. “Mablink et Agatha partagent un engagement en faveur de la vitesse de l’innovation, garantissant que les nouvelles avancées médicales soient disponibles pour les patients dès que possible et en toute sécurité,” a déclaré Guillaume. “Nous sommes impatients d’être un partenaire de Mablink dans la lutte contre le cancer.”

À propos de Mablink

Mablink Bioscience est une société de biotechnologie française fondée en 2018, spécialisée dans le développement d’une nouvelle classe de médicament contre le cancer, les anticorps thérapeutiques conjugués à des molécules-médicaments (appelés ADC – Antibody Drug Conjugate). Mablink capitalise sur son expertise en chimie, pharmacologie et immuno-oncologie et sur sa plateforme technologique brevetée pour concevoir des ADC de 3e génération ayant un index thérapeutique amélioré. La plateforme technologique de Mablink est universelle et s’adapte à tout type d’anticorps thérapeutiques et tout type de molécule-médicament. Elle permet de concevoir des ADC de 3e génération, hautement chargés en molécules-médicaments tout en conservant d’excellentes propriétés pharmacologiques, afin d’augmenter l’efficacité des traitements ciblés dans les cancers avancés.

À propos d’Agatha, Inc.

Agatha, Inc. est l’un des principaux fournisseurs de solutions logicielles stratégiques pour l’industrie des soins de santé et des sciences de la vie. Agatha se consacre à aider les hôpitaux, les sociétés des biotechnologies, les laboratoires pharmaceutiques, les organisations de recherche contractuelle et les sociétés de dispositifs médicaux du monde entier à optimiser la gestion de leur documentation et de leurs processus de qualité, réglementaires et cliniques.

Les solutions Agatha sont disponibles immédiatement, sont conformes aux réglementations applicables (telles que la FDA 21 CFR partie 11 et sont conçues pour une adoption rapide et une mise à l’échelle efficace. Les clients d’Agatha sont en mesure de réduire immédiatement leur risque de conformité et d’augmenter leur productivité. Ils réduisent le temps passé à gérer en moyenne 80% de leur documentation clinique, qualité et réglementaire Agatha est le partenaire de confiance de plus de 200 hôpitaux, centres de recherche, CRO, laboratoires pharmaceutiques et sociétés de dispositifs médicaux dans le monde.

Company Name: Agatha Inc.
Representative Director: Chiemi Kamakura
Office: 2F FtF Bldg, 1-2 Hakozaki-cho, Nihombashi, Chuo-ku, Tokyo 103-0015 Japan
Date of incorporation: October 2, 2015
Amount of capital: 535 million JPY (including legal capital surplus)

Yasuyo Susukida

MABLINK BIOSCIENCE Adopts Agatha Software Solutions

Mablink partnership

Tokyo, Japan; Lyon, France; Boston, USA, January 10, 2020 – Agatha Inc., a global leader in quality and content management solutions for life sciences, today announced that Mablink Bioscience, a French-based biotech company specialized in immuno-oncology, is adopting Agatha’s solution.

Mablink aims to democratize the development of 3rd generation Antibody-Drug Conjugates (ADCs), which is a new class of cancer drugs. Mablink’s approach is rooted in its expertise in chemistry, pharmacology, and immuno-oncology in order to develop a hydrophilic easy-to-implement platform for next-generation ADCs.

“By equipping our company with the solution developed by Agatha, we want to give ourselves the possibility to scale swiftly and to be able to professionally manage the requests of our customers and partners.  The willingness to structure our processes with scalable solutions like Agatha’s, from the beginning, is part of our strategy,” said Jean-Guillaume Lafay, CEO of Mablink.

According to Guillaume Gerard, Chief Operating Officer of Agatha, Inc., innovators like Mablink need to have solutions that are fast to deploy and easy to use, so they can adopt them quickly and scale their use rapidly.

“Mablink and Agatha share a commitment to speed and innovation, ensuring that new medical advances are available to patients as soon as safely possible,” said Guillaume. “We look forward to being a partner to Mablink in their fight against cancer.”

About Mablink

Mablink Bioscience is a French-based biotechnology company founded in 2018, specialized in the development of a new class of cancer drug, called Antibody Drug Conjugate (ADC). Mablink leverages its expertise in chemistry, pharmacology, and immuno-oncology and its patented technological platform to design 3rd generation ADCs that are less toxic, more efficient and easy to manufacture. Mablink’s technological platform is universal and adapts to all types of drug-molecule. Moreover, it makes it possible to design 3rd generation ADCs that are highly loaded with drug molecules while retaining excellent pharmacological properties, in order to increase the effectiveness of targeted therapies in advanced cancers.

About Agatha, Inc.

Agatha, Inc. is a leading strategic software solutions provider to the health care and life sciences industry. Agatha is dedicated to helping the world’s Hospitals, biotechnology, pharmaceutical, contract research organizations, and medical device firms optimize the management of their Quality, Regulatory and Clinical documentation and processes.

Agatha solutions are available immediately, are compliant with applicable regulations (such as FDA 21 CFR part 11 and are designed for rapid adoption and effective scaling. Agatha’s clients are able to immediately decrease their compliance risk and increase their productivity; they reduce the time spent to manage their clinical, quality and regulatory documentation by 80% on average. Agatha is the trusted partner of more than 200 hospitals, research centers, CROs, pharmaceutical companies and medical device companies worldwide.


Company Name: Agatha Inc.
Representative Director: Chiemi Kamakura
Office: 2F FtF Bldg, 1-2 Hakozaki-cho, Nihombashi, Chuo-ku, Tokyo 103-0015 Japan
Date of incorporation: October 2, 2015
Amount of capital: 535 million JPY (including legal capital surplus)

US Contact:
Ken Lownie
phone: 1 978.618.2363

The Lines are Blurring Between Clinical Trial Management Software Categories

clinical trial software

I find myself back in the world of life sciences software after an absence of several years, and as with any return to a place of one’s memory, my reentry has sharpened my vision, revealing patterns I may have missed if I never left.

One thing I see is how clinical trial software has evolved with separate and distinct solutions for different aspects of managing clinical trials. There is Electronic Data Capture (EDC) for collecting trial data, Electronic Clinical Trial Management Systems (eCTMS) for planning and managing the trial, and electronic Trial Master Files (eTMF) solutions for managing trial documentation. And there many other solutions for enrollment, managing payments, and handling the actual medications.

But here is the question that jumps out at me:

Why have we evolved these distinct categories of trial management software?

Building Clinical Trial Software – The Old Way

Sometimes, the separations make perfect sense to me. When different users have different needs and work through different processes, good design says the applications they use should probably be separate.

But sometimes the dividing lines are based on differences in technology, not the needs of users. Specifically, there have evolved distinct and separate categories of software not based on the needs and roles of specific groups of users, but on the different types of information that you need to manage in a study.

Here is what I mean. EDC software is all about data: the information at the heart of the EDC solution is highly-structured data… that is, quantitative data, structured for analysis.

Conversely, the focus of eTMF solutions is on documents, not structured data, and there is a separate category of solutions for that area using document management technologies.   Additional solutions in the CTMS category focus on managing the schedules and processes of a trial.

Notice the way things evolved? One category for data, one for documents and one for the schedule and processes.

The lines of demarcation are not necessarily where they should be, and I think we are starting to see a “refactoring” of functions as different solutions evolve and reflect the needs of specific users in specific roles.

Building Clinical Trial Software for Users – The Right Way

We do not need to separate functions and activities because the type of information is different. We need applications that combine structured data and unstructured data, database rows and columns with metadata and workflow processes in easy-to-use interfaces designed around a user’s roles and tasks.

Returning to the world of life sciences software with my sharpened vision, I am happy that this shift is happening. As I look at current eTMF solutions like Agatha’s, I see an application that combines the management of documents with a forms-based model that collects and stores structured information, and then adds workflow capabilities to define processes. In one system, a user can create and manage the documents that define the TMF but also manage the processes relating to the documents and collect and store structured data through forms-based entry.

Today, instead of a limiting factor, the technology available to us enables this ability to mix information types in an application. That’s because even though the regulatory authorities still require specific documents in specific formats, we can work with structured data to facilitate processes and reuse and then generate the documents from that data when we need them.

The ability to work in this way, with structured data, documents and other types of data, means that we can design better applications. And when I say better, I mean applications that reflect exactly the processes and activities of a specific set of users.

As this trend accelerates, I think we will see software solutions that increasingly group functions based on roles and tasks. These applications will be easier to use, resulting in users adopting them more quickly, which is essential given the economics of clinical trials.

And the best part is that we are just at the start of this shift. I realize we are at the dawn of a new generation of solutions that are more aligned with user roles, incorporate advanced AI technologies and adopt the best user interfaces.  It is an exciting time, and for me, it is good to be back 🙂

Interested in learning more about Agatha’s solutions? Drop me a quick email and we can chat.

Copy link
Powered by Social Snap